Senetek PLC (SNKTY)

[BioSpecialist]

Stock recommendation: Senetek PLC (sntky.ob)



We believe this stock is great buy at this very low price, and has lots of potential for a large upwards move in stock price in the range $3-10 in 2010 (250%-700%)

Senetek Fact Sheet

This is a very undervalued stock which has been living a quiet life on Nasdaq.

As of today (1. November 2009) it is priced at 1.3, which is less than the book value of the company!

Senetek has $12 million in cash and no debt! With about 8.5 million shares, it gives a P/B ratio of 12/8.5=1.41

Senetek PLC has a very valuable product and patent portfolio, from which it could gain hugh rises in profits over the next 1-5 years.
The company operates in two segments,

Skincare and Pharmaceutical:

Skincare

The Skincare segment offers Pyratine-6, a second generation cytokinin for the treatment of aging skin;
Pyratine XR for the visible signs and symptoms associated with various conditions, such as rosacea, eczema, contact dermatitis, and menopause;
(These have already been launched in 2009)

4HBAP, an aromatic cytokinin for the treatment of photodamaged skin and its effect on the reduction of erythema; and
(To marked in 1Q 2010)

Kinetin, a first generation cytokinin that is a plant growth factor, which retards senescence of plants and delays age-related changes in cultured human skin cells.
(Sold rights to Kinetin to VALEANT PHARMA which has had a hugh succes with it in the product line Kinerase)

Pharmaceutical:
The Pharmaceutical segment offers Invicorp, an intracavernous injection therapy for the treatment of male erectile dysfunction;
In has been approve for sale in Denmark, and partly in the UK. Pending PDA approval in US

Reliaject, an autoinjector system; and diagnostic monoclonal antibodies that are used in Alzheimer’s and other disease research.

Research
The company has research and collaboration agreements with the Institute of Experimental Botany in Prague, the Czech Republic for the research on plant physiology, genetics, and biotechnology;
Institute of Bioorganic Chemistry of the Polish Academy of Sciences in Poznan, Poland for the rights to three compounds for the treatment of skin aging, and technology used for the treatment of brain tumors using interference RNA; and PROTEOMAGE, the European integrated project on healthy aging.

It operates primarily in the United States, the United Kingdom, and Denmark. Senetek PLC was founded in 1983 and is headquartered in Napa, California.


Why is Senetek a great buy?

No matter which if the strategies below Senetek chooses in 2009 - 2010, it will push the price of the stock to a much higher level:

* It keeps it independency and let its sales grow organically. (likelihood 25%) (slower but steady rise in the share price in 2010, price $2-5 )
* It may sell of the Invicorp and Reliaject products and focus on the skincare sales, (likelihood 25%) (jump in price, and then slower but steady rise in the share price in 2010, a jump to $3-4 then move steadily to $6-7)
* May want merge, be bought by a larger skin-care company to better utilize sales channels, marketing etc. (likelihood 50%)(Large jump in price, $6-10)


and

* It has a shareholder approved share buy-back plan put in to place, which may start at any time.
* Senetek will move listing to a larger exchange in the future, this alone will boost the stock price
* The CEO has a large amount of shares and options and has very strong incentives to move the stock price to a much higher level

[BioSpecialist]

EU-Approval soon

Market-cap 10,6 M$

Huge upside potential here

[BioSpecialist]

SENETEK IS SOOOO UNDERVALUED !!!

Mcap 10 M$
Cash 13 M$

Senetek PLC Acquires Rights To Additional Anticancer RNAi Technology


Senetek PLC announced an agreement with the Institute of Bioorganic Chemistry of the Polish Academy of Sciences in Poznan, Poland for the exclusive rights to a new and promising tumor treatment using an RNAi based therapeutic technology for the potential use against a broad range of cancers. This technology, which specifically targets a cancer biomarker, was developed by the Institute in cooperation with Department of Neurosurgery and Neurotraumatology University of Medical Sciences in Poznan, Poland. Under the terms of the collaborative agreement, Senetek will have rights for all applications of the in-licensed technologies in exchange for undisclosed royalty payments to be paid to the Institute upon commercialization.

[BioSpecialist]

BREAK OUT SOON


http://quote.barchart.com/texpert.asp?sym=SNKTY

[BioSpecialist]

PARTNER NEWS FOR INVICORP SOON

[BioSpecialist]

Up again

2$ very soon ---

[BioSpecialist]

THIS UNDERVALUED STOCK IS FLYING UNDER RADAR !!!

Senetek (SNKTY.OB)

Market Cap : 9 M$
Cash : 13 M$ (NO DEBT)
Price : 1,20 $

Shares Out : 7,65 Mio

Pipeline
http://www.senetekplc.com/view_our_pipeline.asp

Analyst Report ..Read
http://www.senetekplc.com/SenetekPLC-IntelligenceDynamicsResearchReport.pdf


Senetek PLC
(OTC Bulletin Board: SNKTY.OB)
Senetek is a Life Sciences company engaged in the development of technologies
that target the science of healthy aging. The Company’s extensive research
collaborations have resulted in a strong pipeline of patented compounds and
products with broad therapeutic applications and a leading presence in
dermatology. Senetek collaborates with established specialty pharmaceutical
companies in the final development and marketing of its proprietary products, most
recently resulting in the development of the best-selling anti-aging product sold in
the North American physician market.
Lead Products
Pyratine-6™
(0.1% Furfuryl Tetrahydropyranyladenine)
The first in Senetek’s new generation cytokinin pipeline to complete development,
Pyratine-6™ has demonstrated, through clinical trials, superior results and faster
onset of action in treating photodamaged skin when compared to Senetek’s highly
successful predecessor compounds.
In September 2008, Senetek launched the Pyratine-6™ family of products in the
North America Physician market.
The Company is actively seeking marketing collaboration agreements for other
geographies.
Pyratine XR™
(0.125% Furfuryl Tetrahydropyranyladenine)
Based on positive results demonstrated in Pyratine-6™ clinical evaluations,
Senetek initiated a clinical trial of 0.125% Furfuryl Tetrahydropyranyladenine for
the reduction of visible signs and symptoms associated with various conditions
such as rosacea, eczema, contact dermatitis and menopause. Rosacea is a chronic
dermatosis afflicting more than 14 million people in North America and 45 million
people worldwide.
An overall clinical improvement was noted in 80% of subjects, including reduction
of erythema and papules. The investigators saw continual, statistically significant
mean improvement with Pyratine XR™ treatment, including a 90% improvement
in lesions, 45% improvement in erythema and a 28% improvement in
telangiectasia
Pyratine XR™ Crème and Lotion were launched in the North American Physician
market in March 2009.
The Company is actively seeking marketing collaboration agreements for other
geographies
Kinetin
Senetek scientists developed and patented the cytokinin Kinetin as an anti-aging
compound. Senetek commercialized Kinetin under the Kinerase® trademark, which
is now owned by Valeant Pharmaceuticals Inc. Kinerase® is currently the leading
anti-aging compound sold in the North American physician market. In early 2007,
Senetek sold Valeant a perpetual use license for Kinetin for $21 million,
forgiveness of a $6 million prepaid royalty credit reimbursement obligation that
Senetek otherwise would have owed to Valeant, and a right to share in future
royalties due to Valeant from other Kinetin licensees through 2011.

Invicorp®
Senetek has entered into a partnership agreement with Plethora Solutions
Limited (LSE-AIM: PLE), for the commercialization of Invicorp® in North
America. Under this agreement, Plethora assumes full financial responsibility
for all future development, regulatory approvals, and sales and marketing of the
product. Senetek will participate in the success of Invicorp® through milestone
payments and royalties based on net sales. The European marketing rights,
previously licensed to Ardana Biosciences Ltd, were returned to Senetek when
Ardana entered receivership in June 2008. An evaluation of the Company’s
options regarding redeployment of the European marketing rights as well as
rights for the rest of the world is currently underway.
Reliaject®
Reliaject® is an advanced drug delivery system for self-administration of
parenteral drugs, including epinephrine for emergency treatment of anaphylaxis,
a severe allergic reaction that occurs in response to food, insect venom or
medication – currently a $250 million market in North American alone.
Reliaject® is also well suited to other injectable therapies including Senetek’s
Invicorp® for the treatment of ED. The company entered an agreement with
Ranbaxy Pharmaceuticals, through which Senetek will receive future milestone
payments, as well as royalties paid out over 15 years on all products introduced
in the Reliaject® drug delivery system.
Research & Development
Senetek’s scientific research collaborations form the basis for a continuous,
interactive flow of new product identification, evaluation and testing activity
between the University of Aarhus, Senetek’s dedicated laboratory in Denmark,
the Institute of Experimental Botany in the Czech Republic, the University of
California-Irvine, and the Institute of Bioorganic Chemistry of the Polish
Academy of Sciences among others. Through these collaborations the Company
has greatly expanded its IP portfolio, adding many vital technologies, while
accelerating product development.
Pipeline
Senetek’s partnerships with leading research and academic institutions have
placed the Company at the forefront of technological advancements in the
science of aging. The Company’s large and growing IP portfolio features new
models in treatment that span a range of therapeutic areas including
dermatology, nutrition, wound healing and erectile dysfunction.
Market Opportunity
Owing to an increase in health awareness and continued progress in the field of
science and medicine, the average global life span has seen a steady rise over the
past several decades, a trend that is only expected to become more pronounced
in the decades to come. According to the United Nations, the percentage of the
world’s population over the age of 60 is expected to rise from 10.0% in 2000 to
22.1% in 2050. In more developed regions, such as Europe and North America,
these percentages are anticipated to be even higher, estimated at approximately
35.0% and 27.0%, respectively, by 2050. The aging of society is likely to create
increased opportunity for treatments and therapies such as those based on
Senetek’s patented compounds.
Business Model
With a strong balance sheet in place, the Company has transitioned from a
licensing model to a sales and marketing model, delivering an increased revenue
stream with higher margin potential and creating long-term value for its
shareholders.

[di4]

Senetek PLC Investor Hotline Goes Live
May 15, 2009 4:30:00 PM


Email Story Discuss on ZenoBank

View Additional ProfilesCall 877-SENETEK or 707-259-6278


NAPA, Calif., May 15 /PRNewswire-FirstCall/ -- Senetek PLC (OTC Bulletin Board: SNKTY), a Life Sciences company engaged in the development of technologies that target the science of healthy aging, announced that an up-to-date audio recording of Company news and developments is now available by calling 877-SENETEK in the United States and Canada and 707-259-6278 from international locations.


"We are pleased to provide this service to our investors as a supplement to news releases, shareholder teleconferences and our quarterly and annual filings. Our mission is to keep the Senetek shareholder updated in a timely fashion," stated Frank J. Massino, Chairman and Chief Executive Officer of Senetek.


About Senetek PLC:

Senetek PLC (OTCBB: SNKTY) is a life sciences company engaged in the development of breakthrough technologies that target the science of healthy aging. The company's extensive research collaborations have resulted in a strong pipeline of patented compounds and products with broad therapeutic applications and a leading presence in dermatology. Senetek collaborates with established specialty pharmaceutical companies in the final development and marketing of its proprietary products, most recently resulting in the development of kinetin, the best-selling anti-aging product sold in the North American physician market. For more information, visit the company's websites:


www.senetekplc.com


www.pyratine6.com


www.pyratinexr.com


or call: 877-SENETEK (United States and Canada) 707-259-6278 (International Locations)


This news release contains statements that may be considered 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act. Forward-looking statements by their nature involve substantial uncertainty, and actual results may differ materially from those that might be suggested by such statements. Important factors identified by the Company that it believes could result in such material differences are described in the Company's Annual Report on Form 10-K for the year 2008. However, the Company necessarily can give no assurance that it has identified or will identify all of the factors that may result in any particular forward-looking statement materially differing from actual results, and the Company assumes no obligation to correct or update any forward-looking statements which may prove to be inaccurate, whether as a result of new information, future events or otherwise.





SOURCE Senetek PLC



----------------------------------------------
William O'Kelly of Senetek
PLC
[phone]
ext. 102 or Media
Maggie Carr
[e-mail]
or Michael Rogers
[e-mail]
both of Michael Rogers Public Relations
[phone]
ext. 22
for Senetek
PLC

[di4]

Senetek PLC Reports First Quarter 2009 Financial Results
May 15, 2009 4:20:00 PM


Email Story Discuss on ZenoBank

View Additional ProfilesNAPA, Calif., May 15 /PRNewswire-FirstCall/ -- Senetek PLC (OTC Bulletin Board: SNKTY), a Life Sciences company engaged in the development of technologies that target the science of healthy aging, announced results for the quarter ended March 31, 2009.


Revenue for the quarter ended March 31, 2009 was $461,000, compared with $230,000 reported in the fourth quarter of 2008 and $441,000 reported in the first quarter of 2008.


Revenues from Pyratine product sales in the first quarter of 2009 were $93,000 compared to $43,000 and $89,000 in the fourth quarter of 2008 and the first quarter of 2008, respectively. Pyratine XR(TM), launched in March 2009 made a limited contribution to first quarter 2009 sales due to the timing of the product launch.


Royalty revenue on sales of monoclonal antibodies totaled $323,000 in the first quarter of 2009 compared to $145,000 and $279,000 in the fourth quarter of 2008 and the first quarter of 2008, respectively.


Revenues in the first quarter of 2008 included $30,000 in product sales of Kinetin raw material and formulated products. Other quarterly sources of revenues were comparable between the first quarter of 2009 and the fourth and first quarters of 2008.


Net loss for the quarter ended March 31, 2009 totaled $1,147,000 or $0.15 per diluted share compared to a net loss of $1,209,000 or $0.16 per diluted share for the quarter ended December 31, 2008 and a net loss of $1,757,000 or $0.23 per diluted share for the quarter ended March 31, 2008.


In March, the Company launched Pyratine XR(TM) at the 67th Annual Meeting of the American Academy of Dermatology. In one rosacea specific study performed at the University of California, Irvine, data demonstrated that Pyratine XR(TM) showed continual improvement for all of the major symptoms of rosacea - redness, lesions and spider veins - throughout the entire course of a 48 week treatment period. This suggests that Pyratine XR(TM) may offer important advantages over currently available treatments for rosacea, many of which have issues with long-term tolerability. Since rosacea is a chronic condition that often requires extended treatment periods with topical agents that can cause high skin sensitivity, treatments that provide sustained relief of the signs and symptoms of rosacea are needed.


About Senetek PLC:

Senetek PLC (OTCBB:SNKTY) is a life sciences company engaged in the development of breakthrough technologies that target the science of healthy aging. The company's extensive research collaborations have resulted in a strong pipeline of patented compounds and products with broad therapeutic applications and a leading presence in dermatology. Senetek collaborates with established specialty pharmaceutical companies in the final development and marketing of its proprietary products, most recently resulting in the development of kinetin, the best-selling anti-aging product sold in the North American physician market. For more information, visit the company's websites www.senetekplc.com


www.pyratine-6.com


www.pyratinexr.com


This news release contains statements that may be considered 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act. Forward-looking statements by their nature involve substantial uncertainty, and actual results may differ materially from those that might be suggested by such statements. Important factors identified by the Company that it believes could result in such material differences are described in the Company's Annual Report on Form 10-K for the year 2008. However, the Company necessarily can give no assurance that it has identified or will identify all of the factors that may result in any particular forward-looking statement materially differing from actual results, and the Company assumes no obligation to correct or update any forward-looking statements which may prove to be inaccurate, whether as a result of new information, future events or otherwise.



SOURCE Senetek PLC



----------------------------------------------
William O'Kelly of Senetek
PLC
[phone]
ext. 102
or Maggie Carr
[e-mail]
or Michael Rogers
[e-mail]
both of Michael Rogers Public Relations
[phone]
ext. 22

[di4]

Spotlight on Rosacea Advance - May Issue of Journal of Drugs in Dermatology Features Pyratine XR(TM) Clinical Study
May 4, 2009 9:00:00 AM


Email Story Discuss on ZenoBank

View Additional Profiles- 12-week study concludes that new cosmeceutical improves skin barrier function, erythema and lesions associated with rosacea -


NAPA, Calif., May 4 /PRNewswire-FirstCall/ -- Senetek PLC (OTC Bulletin Board: SNKTY), a life sciences company engaged in the development of technologies that target the science of healthy aging, today announced that the clinical study entitled "Topical PRK-124 (0.125%) Lotion for Improving the Signs and Symptoms of Rosacea," has been published in the May issue of Journal of Drugs in Dermatology, a peer-reviewed dermatologic publication.


"We are extremely pleased that the University of California, Irvine, study has been published in the Journal of Drugs in Dermatology," stated Frank Massino, Chairman and Chief Executive Officer of Senetek PLC. "As one of the most highly-respected and well-read publications in the dermatologic field, there is no better means to substantiate and communicate this scientific advancement to physicians interested in rosacea."


The 12-week, open-label study concludes that Pyratine XR(TM) (0.125% furfuryl tetrahydropyranyladenine) improved skin barrier function and the appearance of erythema (redness) and lesions (pustules and papules) associated with mild-to-moderate rosacea during 12 weeks of treatment.


According to study data, Pyratine XR(TM) produced a progressive decrease in the symptoms associated with rosacea, with an overall clinical improvement in 80% of subjects, including reduction of redness and lesions. Transepidermal water loss measurements showed a 22% decrease, which supports an improvement in skin barrier function, with a 41% mean improvement in skin dryness as early as week four. All subject self-assessments showed good tolerability and cosmetic acceptability.


"Current treatments for rosacea, like oral and topical antibiotics, possess long-term tolerability and other health concerns that affect the more than 14 million Americans suffering from rosacea," said Dr. Arisa Ortiz, clinical research fellow and investigator on the Pyratine XR clinical research trial. "The study data is promising for rosacea sufferers and suggests that Pyratine XR can improve rosacea symptoms without adverse effects. The findings definitely warrant further research."


To read the article in full, please visit www.jddonline.com or www.PyratineXR.com.


About Senetek PLC

Senetek PLC (OTCBB:SNKTY) is a life sciences company engaged in the development of breakthrough technologies that target the science of healthy aging. The company's extensive research collaborations have resulted in a strong pipeline of patented compounds and products with broad therapeutic applications and a leading presence in dermatology. Senetek collaborates with established specialty pharmaceutical companies in the final development and marketing of its proprietary products, most recently resulting in the development of kinetin, the best-selling anti-aging product sold in the North American physician market. For more information, visit the company's website at www.senetekplc.com.




SOURCE Senetek PLC



----------------------------------------------
William O'Kelly of Senetek PLC
[phone]
ext. 102; or Media
Maggie Carr
[e-mail]
or Michael Rogers
both of Michael Rogers Public Relations
[phone]
ext. 22
for Senetek PLC